Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Harmony Biosciences Holdings Inc before investing.

In this article, we go over a few key elements for understanding Harmony Biosciences Holdings Inc’s stock price such as:

• Harmony Biosciences Holdings Inc’s current stock price and volume
• Why Harmony Biosciences Holdings Inc’s stock price changed recently
• Upgrades and downgrades for HRMY from analysts
• HRMY’s stock price momentum as measured by its relative strength

About Harmony Biosciences Holdings Inc (HRMY)

Before we jump into Harmony Biosciences Holdings Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Want to learn more about Harmony Biosciences Holdings Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc’s Stock Price as of Market Close

As of June 21, 2024, 4:00 PM, CST, Harmony Biosciences Holdings Inc’s stock price was $30.13.

Harmony Biosciences Holdings Inc is up 4.58% from its previous closing price of $28.81.

During the last market session, Harmony Biosciences Holdings Inc’s stock traded between $28.57 and $29.16. Currently, there are 56.77 million shares of Harmony Biosciences Holdings Inc stock available for purchase.

Harmony Biosciences Holdings Inc’s price-earnings (P/E) ratio is currently at 12.4, which is low compared to the Pharmaceuticals industry median of 22.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Harmony Biosciences Holdings Inc Stock Price History

Harmony Biosciences Holdings Inc’s (HRMY) price is currently up 2.48% so far this month.

During the month of June, Harmony Biosciences Holdings Inc’s stock price has reached a high of $30.57 and a low of $28.57.

Over the last year, Harmony Biosciences Holdings Inc has hit prices as high as $39.27 and as low as $18.61. Year to date, Harmony Biosciences Holdings Inc’s stock is down 45.32%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Harmony Biosciences Holdings Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 20, 2024, there were 6 analysts who downgraded Harmony Biosciences Holdings Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Harmony Biosciences Holdings Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Harmony Biosciences Holdings Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Harmony Biosciences Holdings Inc’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Harmony Biosciences Holdings Inc (HRMY) by visiting AAII Stock Evaluator.

Relative Price Strength of Harmony Biosciences Holdings Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 20, 2024, Harmony Biosciences Holdings Inc has a weighted four-quarter relative price strength of -12.52%, which translates to a Momentum Score of 30 and is considered to be Weak.

Want to learn more about how Harmony Biosciences Holdings Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Harmony Biosciences Holdings Inc Stock Price: Bottom Line

As of June 21, 2024, Harmony Biosciences Holdings Inc’s stock price is $30.13, which is up 4.58% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Harmony Biosciences Holdings Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.